Intervention

Avelumab

ClinicalTrials.gov intervention label

Clinical trials44
Recruiting3
Common conditions25
Lead sponsors shown15

Clinical trials

44 shown
Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)NCT06228066 · 2024-06-13
RECRUITING
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic CancerNCT05267626 · 2022-04-04
RECRUITING
Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast CancerNCT04841148 · 2021-06-01
RECRUITING
Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )NCT06939036 · 2025-07-01
TERMINATED
A Proof of Concept Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast CancerNCT04188119 · 2023-12-01
WITHDRAWN
FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid TumorsNCT05395052 · 2022-05-31
TERMINATED
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted AntibodiesNCT04902040 · 2021-04-14
TERMINATED
GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 TherapyNCT04601402 · 2020-10-26
COMPLETED
Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal TherapyNCT04071236 · 2020-10-14
ACTIVE_NOT_RECRUITING
Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid TumorsNCT04571632 · 2020-09-22
UNKNOWN
FT516 in Combination With Monoclonal Antibodies in Advanced Solid TumorsNCT04551885 · 2020-09-07
TERMINATED
PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast CancerNCT04360941 · 2020-08-11
ACTIVE_NOT_RECRUITING
A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 StudyNCT04215146 · 2020-06-10
ACTIVE_NOT_RECRUITING
Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)NCT04173507 · 2020-02-14
COMPLETED
A Proof of Concept, Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast CancerNCT03794596 · 2019-09-01
WITHDRAWN
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast CancerNCT03971409 · 2019-07-08
ACTIVE_NOT_RECRUITING
A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid TumorsNCT03861403 · 2019-05-20
TERMINATED
TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast CancerNCT03964532 · 2019-04-19
ACTIVE_NOT_RECRUITING
Avelumab Program Rollover StudyNCT03815643 · 2019-03-22
ACTIVE_NOT_RECRUITING
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid TumorsNCT03845166 · 2019-03-20
ACTIVE_NOT_RECRUITING
Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPCNCT03770455 · 2019-01-25
TERMINATED
Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast CancerNCT03573648 · 2018-11-13
ACTIVE_NOT_RECRUITING
Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLCNCT03717155 · 2018-10-30
COMPLETED
PD-L1 Imaging in Non Small Cell Lung Cancer' (PINNACLE)NCT03514719 · 2018-10-01
COMPLETED
Immunotherapy in Combination With Chemotherapy in Small-cell Lung CancerNCT03568097 · 2018-09-16
UNKNOWN
QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) VaccineNCT03554109 · 2018-09-01
WITHDRAWN
The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast CancerNCT03414658 · 2018-06-21
ACTIVE_NOT_RECRUITING
QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung CancerNCT03574649 · 2018-06-01
WITHDRAWN
PD-L1 Inhibition as ChecKpoint Immunotherapy for NeuroEndocrine Phenotype Prostate CancerNCT03179410 · 2018-02-01
COMPLETED
Stereotactic Body Radiation Therapy and Avelumab Immunotherapy for Treatment of Malignant MesotheliomaNCT03399552 · 2017-12-20
COMPLETED
Survival Prolongation by Rationale Innovative GenomicsNCT03386929 · 2017-11-29
TERMINATED
SBRT Combined With Avelumab (Anti-PD-L1) for Management of Early Stage Non-Small Cell Lung Cancer (NSCLC)NCT03050554 · 2017-10-26
TERMINATED
A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based TherapyNCT03270176 · 2017-10-10
COMPLETED
Palbociclib After CDK and Endocrine Therapy (PACE)NCT03147287 · 2017-09-05
ACTIVE_NOT_RECRUITING
Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced MalignanciesNCT03217747 · 2017-08-02
ACTIVE_NOT_RECRUITING
UCDCC#270: Avelumab and Stereotactic Ablative Radiotherapy in Non-responding and Progressing NSCLC PatientsNCT03158883 · 2017-05-17
COMPLETED
A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based ChemotherapyNCT03076554 · 2017-04-19
ACTIVE_NOT_RECRUITING
Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant GlioblastomaNCT02968940 · 2017-03-17
COMPLETED
Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)NCT02584634 · 2015-12-18
TERMINATED
A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)NCT02554812 · 2015-11-09
TERMINATED
Avelumab in First-line NSCLC (JAVELIN Lung 100)NCT02576574 · 2015-10-29
COMPLETED
Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)NCT02349633 · 2015-05-14
TERMINATED
Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200)NCT02395172 · 2015-03-24
COMPLETED
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)NCT01772004 · 2013-01-31
COMPLETED

Common conditions

Breast Cancer7Non Small Cell Lung Cancer5Non-Small Cell Lung Cancer3Solid Tumors3Advanced Malignant Solid Neoplasm2Carcinoma, Non-Small-Cell Lung2Colorectal Cancer2Metastatic Breast Cancer2Metastatic Castration-resistant Prostate Cancer2Solid Tumor2Stage IV Lung Cancer AJCC v82Stage IVA Lung Cancer AJCC v82Stage IVB Lung Cancer AJCC v82Stage IVB Prostate Cancer AJCC v82Advanced Bladder Carcinoma1Advanced Cancer1Advanced Hormone Receptor Positive/Endocrine Refractory Breast Cancer1Advanced Lung Non-Small Cell Carcinoma1Advanced Lung Non-Squamous Non-Small Cell Carcinoma1Advanced Melanoma1Advanced Merkel Cell Carcinoma1Advanced Metastatic Castration-Resistant Prostate Cancer1Advanced Platinum-Resistant Ovarian Cancer1Advanced Renal Cell Carcinoma1Advanced Solid Tumor1

Trial status mix

ACTIVE_NOT_RECRUITING12
COMPLETED12
TERMINATED11
WITHDRAWN4
RECRUITING3
UNKNOWN2

Phase mix

PHASE231
PHASE121
PHASE33
EARLY_PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.